Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Presentation TCT 2025

TCT 1271: Safety and Efficacy of Biodegradable Polymer-coated Sirolimus-eluting Stent in the Treatment of Octo- and Nonagenarian All Comer Patients with Coronary Artery Disease – Results from the Prospective Multicenter Cruz Senior Study

Presenter: Gregor Nelles

October 28, 2025

Presentation TCT 2025

TCT 1957: Improved Outcomes for In-Stent Restenosis PCI With Use of Sirolimus Eluting Ultra-thin Stent Platform

Presenter: Jared Romeo

October 28, 2025

Presentation TCT 2025

TCT 891: Safety and clinical performance of the Yukon Choice PC, Yukon Chrome PC & Yukon Choice Flex Sirolimus Eluting Bioabsorbable Polymer Stents Systems in Routine Clinical Practice: e-Yukon Global Registry.

Presenter: Bimmer E. Claessen

October 28, 2025

Presentation TCT 2025

TCT 519: Sirolimus eluting balloon efficacy and safety. A prospective registry of large vs small vessels

Presenter: Marco Ferrone

October 28, 2025

Presentation TCT 2025

TCT 889: A Multicenter Observational Study in France Assessing Sirolimus-Eluting Biodegradable Polymer Stent for CAD Patients Undergoing PCI in Routine Clinical Practice

Presenter: Adnan Kastrati

October 28, 2025

Presentation TCT 2025

TCT 529: Clinical Outcomes after Scoring-balloon and Sirolimus-eluting Balloon Strategy in Diffuse Small-vessel Coronary Artery Disease (SCA-DEB Study)

Presenter: Valery Ljubenov Gelev

October 28, 2025

Presentation TCT 2025

TCT 241: Post Market Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold: Long Term Clinical Outcomes

Presenter: Matthias Lutz

October 28, 2025

Presentation TCT 2025

Sirolimus-Eluting Iron Bioresorbable Scaffold in Coronary Artery Disease: Two-Year Results of IRONMAN-II Randomized Controlled Trial

Presenter: Lei Song

October 27, 2025

Presentation TCT 2025

TCT 233: FANTOM II Study: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – Pooled Analysis From 3 Study Cohorts

Presenter: Matthias Lutz

October 26, 2025

Presentation TCT 2025

TCT 904: Treatment of femoropopliteal disease with a serial, sirolimus-eluting, bioresorbable vascular scaffold system: Results of the First-in-Human EFEMORAL I clinical trial

Presenter: Rym El Khoury

October 26, 2025

Presentation TCT 2025

TCT 461: Long-Term Outcomes of a Sirolimus-Eluting Balloon in Femoropopliteal Lesions: 36-Month Stratified Analysis by Lesion Location from the SELUTION SFA Japan Study

Presenter: Osamu Iida

October 26, 2025

Presentation TCT 2025

Treatment of Femoropopliteal Disease with a Novel Sirolimus-Eluting BRS: First-In-Human Results of the EFEMORAL I Trial

Presenter: Ramon L. Varcoe

October 26, 2025

Presentation TCT 2025

Sirolimus-Eluting Balloon Versus Repeat Drug-Eluting Stenting or Balloon Angioplasty for In-stent Restenosis

Presenter: Donald Cutlip

October 26, 2025

Presentation TCT 2025

One-Year Results of the SELUTION DeNovo Trial Comparing a Strategy of PCI with a Sirolimus-eluting Balloon and Provisional Stenting Versus Systematic DES Implantation to Treat DeNovo Coronary Lesions

Presenter: Christian M. Spaulding

October 26, 2025

Presentation TCT 2025

A Novel Sirolimus-Eluting Iron Bioresorbable Scaffold in Coronary Artery Disease: Technology Description and Clinical Results

Presenter: Lei Song

October 26, 2025

Presentation TCT 2025

TCT 202: Sirolimus-Eluting Iron Bioresorbable Scaffold in Coronary Artery Disease: First Patient-Level Pooled Analysis Comprising Randomized IRONMAN-II Trial and Prospective IRONMAN-III Registry

Presenter: Lei Song

October 26, 2025

Presentation TCT 2025

Angiographic Performance Following PCI With a Sirolimus-Eluting Balloon in De Novo Coronary Artery Lesions: The GINGER Study

Presenter: Antonio Colombo

October 25, 2025

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

L.A. McKeown

April 23, 2025

Advertisement

TCT 1271: Safety and Efficacy of Biodegradable Polymer-coated Sirolimus-eluting Stent in the Treatment of Octo- and Nonagenarian All Comer Patients with Coronary Artery Disease – Results from the Prospective Multicenter Cruz Senior Study

TCT 1957: Improved Outcomes for In-Stent Restenosis PCI With Use of Sirolimus Eluting Ultra-thin Stent Platform

TCT 891: Safety and clinical performance of the Yukon Choice PC, Yukon Chrome PC & Yukon Choice Flex Sirolimus Eluting Bioabsorbable Polymer Stents Systems in Routine Clinical Practice: e-Yukon Global Registry.

TCT 519: Sirolimus eluting balloon efficacy and safety. A prospective registry of large vs small vessels

TCT 889: A Multicenter Observational Study in France Assessing Sirolimus-Eluting Biodegradable Polymer Stent for CAD Patients Undergoing PCI in Routine Clinical Practice

TCT 529: Clinical Outcomes after Scoring-balloon and Sirolimus-eluting Balloon Strategy in Diffuse Small-vessel Coronary Artery Disease (SCA-DEB Study)

TCT 241: Post Market Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold: Long Term Clinical Outcomes

Sirolimus-Eluting Iron Bioresorbable Scaffold in Coronary Artery Disease: Two-Year Results of IRONMAN-II Randomized Controlled Trial

TCT 233: FANTOM II Study: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – Pooled Analysis From 3 Study Cohorts

TCT 904: Treatment of femoropopliteal disease with a serial, sirolimus-eluting, bioresorbable vascular scaffold system: Results of the First-in-Human EFEMORAL I clinical trial

TCT 461: Long-Term Outcomes of a Sirolimus-Eluting Balloon in Femoropopliteal Lesions: 36-Month Stratified Analysis by Lesion Location from the SELUTION SFA Japan Study

Treatment of Femoropopliteal Disease with a Novel Sirolimus-Eluting BRS: First-In-Human Results of the EFEMORAL I Trial

Sirolimus-Eluting Balloon Versus Repeat Drug-Eluting Stenting or Balloon Angioplasty for In-stent Restenosis

One-Year Results of the SELUTION DeNovo Trial Comparing a Strategy of PCI with a Sirolimus-eluting Balloon and Provisional Stenting Versus Systematic DES Implantation to Treat DeNovo Coronary Lesions

A Novel Sirolimus-Eluting Iron Bioresorbable Scaffold in Coronary Artery Disease: Technology Description and Clinical Results

TCT 202: Sirolimus-Eluting Iron Bioresorbable Scaffold in Coronary Artery Disease: First Patient-Level Pooled Analysis Comprising Randomized IRONMAN-II Trial and Prospective IRONMAN-III Registry

Angiographic Performance Following PCI With a Sirolimus-Eluting Balloon in De Novo Coronary Artery Lesions: The GINGER Study

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content